abstract |
A new combination therapy for cardiovascular diseases, in particular essential hypertension, pulmonary hypertension and / or congestive heart failure, is described, which involves administering a synergistic combination of at least one neutral endopeptidase inhibitor, at least one inhibitor of the endothelin-producing system. endogenous and, at least one AT1 receptor antagonist. |